Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million
23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an